3 Medical Instrument Stocks Betting on GenAI to Ease Industry Hurdles
GenAI creates new opportunities for ISRG, ALC and LIVN, even as regulatory, inflation and industry headwinds continue to pressure MedTech.
LIVN - LivaNova PLC
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$84.83
DETAILS
HIGH:
$95.00
LOW:
$76.00
MEDIAN:
$83.00
CONSENSUS:
$84.83
UPSIDE:
8.38%
Stock News
LivaNova PLC (LIVN) Hit a 52 Week High, Can the Run Continue?
LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LivaNova to Announce Second-Quarter 2026 Results
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2026 results on Wed., Aug. 5, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To lis.
LivaNova Reports Improved OSA Outcomes With PolySync Programming
LIVN's PolySync data show an 84.5% AHI response rate in OSA patients, building on OSPREY results for its aura6000 System.
LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced new data showing that use of its PolySync™ programming algorithm increased the cumulative apnea-hypopnea index (AHI) response rate to 84.5% in patients with moderate to severe Obstructive Sleep Apnea (OSA) when treated with proximal hypoglossal nerve stimulation (pHGNS). The findings were presented at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societie.
Jette Nygaard-Andersen Joins LivaNova Board as a New Director
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company's Board of Directors after its Annual General Meeting of shareholders on June 10. “We're pleased to welcome Jette to LivaNova's Board,” said William Kozy, Chair. “She brings deep medtech governance expertise, proven CEO leadership, and a strong track record of transformation, strategic M&A, and digital innovation across complex gl.
LivaNova PLC (LIVN) Shareholder/Analyst Call Prepared Remarks Transcript
LivaNova PLC (LIVN) Shareholder/Analyst Call Prepared Remarks Transcript
LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
LivaNova Appoints Anne Liddy as Chief Legal Officer
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective Augus
LivaNova Appoints Anne Liddy as Chief Legal Officer
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company's global legal and compliance function and serve as a member of the Executive Leadership Team. Liddy brings more than two decades of experience advising global healthcare and life sciences companies on complex legal, regulatory, M&A, and compliance matters. She joins LivaNo.
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardi
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti, who will retire on July 31. Folli will partner closely with Poletti over the coming months to ensure a seamless leadership transition before assuming full responsibility for the business on August 1. Folli will join the LivaNova Executive Leadership Tea.
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Phil Kowalczyk, Chief Strategy and Corporate Development Officer, will participate in a fireside chat on Mon., June 8, 2026, at 8 a.m. Eastern Daylight Time. The discussion will be.
LivaNova (LIVN) Upgraded to Buy: Here's What You Should Know
LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LivaNova PLC (LIVN) Q1 2026 Earnings Call Transcript
LivaNova PLC (LIVN) Q1 2026 Earnings Call Transcript
LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.88 per share a year ago.
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a constant-currency basis as compared to the prior-year period First-quarter U.S. GAAP diluted earnings per share of $0.40 and adjusted diluted earnings per share of $0.98 F.
Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article chronicling the full 12-month data set for the Company's OSPREY randomized controlled trial (RCT). The researchers evaluated the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality, when delivered by LivaNova's aura6000™ System for the treatment of mod.
Aberdeen Group plc Lowers Stock Holdings in LivaNova PLC $LIVN
Aberdeen Group plc trimmed its position in shares of LivaNova PLC (NASDAQ: LIVN) by 89.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,850 shares of the company's stock after selling 220,443 shares during the quarter. Aberdeen Group plc's holdings in
SG Americas Securities LLC Buys 11,066 Shares of LivaNova PLC $LIVN
SG Americas Securities LLC raised its stake in shares of LivaNova PLC (NASDAQ: LIVN) by 83.9% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,257 shares of the company's stock after buying an additional 11,066 shares during the quarter. SG Americas
Price Targets
LivaNova price target raised to $95 from $90 at Mizuho
$95.00
(was $79.12)
Mizuho Securities
LivaNova price target raised to $92 from $83 at KeyBanc
$92.00
(was $78.50)
KeyBanc
LivaNova price target raised to $90 from $85 at Mizuho
$90.00
(was $66.26)
Mizuho Securities
LivaNova price target raised to $76 from $73 at Barclays
$76.00
(was $66.26)
Barclays
LivaNova price target raised to $80 from $70 at Stifel
$80.00
(was $70.29)
Stifel Nicolaus
Livanova (LIVN) PT Raised to $81 at Needham
$81.00
(was $70.29)
Mike Matson
·
Needham
Piper Sandler on Livanova (LIVN): 'Favorite SMID Value Name On Our List'
$85.00
(was $67.33)
Adam Maeder
·
Piper Sandler
LivaNova price target raised to $67 from $58 at Barclays
$67.00
(was $64.95)
Barclays
LivaNova price target raised to $66 from $56 at Goldman Sachs
$66.00
(was $64.95)
David Roman
·
Goldman Sachs
LivaNova initiated with an Overweight at KeyBanc
$81.00
(was $62.08)
Brett Fishbin
·
KeyBanc
LivaNova price target raised to $72 from $70 at Mizuho
$72.00
(was $63.08)
Anthony Petrone
·
Mizuho Securities
LivaNova price target raised to $75 from $70 at Baird
$75.00
(was $63.05)
Robert W. Baird
LivaNova downgraded to Neutral from Buy at Goldman Sachs
$55.00
(was $52.38)
Goldman Sachs
LivaNova price target lowered to $56 from $58 at Barclays
$56.00
(was $39.17)
Barclays
LivaNova price target lowered to $70 from $80 at Mizuho
$70.00
(was $51.05)
Anthony Petrone
·
Mizuho Securities
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
$65.00
(was $53.90)
David Roman
·
Goldman Sachs
LivaNova upgraded to Outperform from Neutral at Baird
$66.00
(was $48.79)
David Rescott
·
Robert W. Baird
Livanova (LIVN) PT Raised to $72 at Stifel
$72.00
(was $53.45)
Rick Wise
·
Stifel Nicolaus
Stifel Reiterates Buy Rating on Livanova (LIVN)
$70.00
(was $53.16)
Rick Wise
·
Stifel Nicolaus
Stifel on Livanova (LIVN): 'Positive News as OSPREY OSA Trial Hits Early Stop Criteria'
$65.00
(was $56.63)
Rick Wise
·
Stifel Nicolaus